Why Human Growth Hormone Is Class C in the UK and Most Peptides Are Not

Somatropin — recombinant human growth hormone — is a Class C controlled drug in the United Kingdom. It appears by name in Part III of Schedule 2 to the Misuse of Drugs Act 1971, alongside somatotropin, somatrem and chorionic gonadotrophin ^[1]. Most peptides appear nowhere in the Act. The difference is not molecular size or sequence. It is a 1996 decision to bring a group of anabolic agents into drugs control, and the fact that most peptides were never put through that process.

This article covers classification and history only: how the list is built, how growth hormone reached it, what control changes, and why its absence for most peptides is not the same as their being unregulated. The general question of UK legal status for peptides is covered elsewhere on this site under the Human Medicines Regulations.

How the Act is built

The Misuse of Drugs Act 1971 works by enumeration. Schedule 2 lists controlled drugs by name in three parts — Class A, Class B and Class C — and the class sets the maximum penalties that attach to offences involving them ^[1]. The offences cover importing and exporting, producing, supplying and possessing controlled drugs, and possession with intent to supply.

The penalties are published by the government. For Class C, possession carries up to two years' imprisonment, an unlimited fine or both, and supply or production up to fourteen years, an unlimited fine or both ^[5]. The same page notes an exception for anabolic steroids, which it is not an offence to possess in the circumstances the Regulations describe ^[5].

The MHRA's borderline guidance summarises the purpose in a sentence: the Act controls drugs that are dangerous or otherwise harmful, and the Home Office list of controlled drugs refers only to the most commonly encountered ones and is not exhaustive ^[6]. The statutory schedule, not any summary list, is the authority.

How growth hormone got there

The entries were added by the Misuse of Drugs Act 1971 (Modification) Order 1996, made on 15 May 1996 and in force from 1 September 1996. Its explanatory note records that it added to Class C the anabolic and androgenic steroids and derivatives, an adrenoceptor stimulant, and a set of polypeptide hormones ^[2].

The Class C list today shows the result in paragraph 1(e) of Part III: chorionic gonadotrophin, clenbuterol, non-human chorionic gonadotrophin, somatotropin, somatrem and somatropin ^[1]. Read together, the grouping says what the Order was doing. These substances were controlled as a family of anabolic agents, and the polypeptide hormones were included because of the company they kept, not because they are peptides.

The broader context of growth hormone's reputation in those years — the early study that launched it and what the randomised trials later found — belongs to the science lane, and the early study behind growth hormone's reputation and what the later trials found is set out there. The legal point here is narrower: the Order scheduled substances by name, and those names are what the Act now controls.

Possession versus supply: the Schedule 4 Part II position

Controlled drugs are further sorted by the Misuse of Drugs Regulations 2001 into schedules that decide which activities are lawful and on what terms. Somatotropin, somatrem and somatropin appear in Part II of Schedule 4 ^[4]. The heading of that Part describes its effect: the drugs in it are excepted from the prohibition on possession, excluded from import and export offences only where the import or export is carried out in person for administration to that person, and subject to specified record and documentation requirements ^[4].

Regulation 4 gives that heading legal force. Paragraph (3) disapplies the possession prohibition for Part II drugs, and paragraph (2) excludes the import and export offences — including the customs offences — only in that narrow in-person case ^[3]. Nothing in either provision touches production or supply, which remain offences carrying the Class C maximum ^[5].

Two statuses on one molecule

Somatropin is also the active substance in authorised medicines, which are prescription-only. That status comes from the Human Medicines Regulations 2012 and attaches to authorised products and how they may be supplied ^[7]. Control under the Misuse of Drugs Act comes from a different statute and attaches to the substance by name ^[1].

A substance can hold both statuses, one, or neither. Somatropin holds both. Most research peptides hold neither: they are not authorised medicines and they are not listed controlled drugs. That is precisely why their position is governed by other questions — presentation under medicines law, above all.

Why most peptides are not scheduled

There is no generic peptide clause in Schedule 2. The Act controls what it names ^[1], and a substance reaches the list through an amending instrument such as the 1996 Order ^[2]. Most peptides sold for research have never been the subject of one. That is an administrative fact about the list, and how a substance becomes a controlled one explains why scheduling behaves like an act rather than a finding.

• Absence from Schedule 2 means the Misuse of Drugs Act does not control the substance. It does not mean the substance is safe, assessed or approved for anything.
• Absence from Schedule 2 does not remove it from medicines law: presentation with medicinal claims can still make a product an unauthorised medicine ^[7].
• Absence from Schedule 2 is not permanent. The list is amended by order, and has been many times since 1971 ^[1].
• A substance's closeness in structure to a listed one does not, on its own, bring it under the Act unless the schedule's own wording covers it ^[1].

What control changes at the border

For an uncontrolled research material, the border questions are the ordinary customs ones: declaration, classification, duty and VAT. For a controlled drug the question comes first and is different. The Act's prohibition on importation is enforced through customs law — regulation 4 refers expressly to the customs offences that apply to a prohibition having effect under the Act ^[3] — so a controlled drug arriving without authority is a prohibited import, and liable to seizure on that ground alone.

That is the practical meaning of the Class C listing for anyone buying research materials. It does not concern how a product is described or which route it takes. It concerns whether the substance itself may lawfully enter, and for a controlled drug the answer depends on authority the buyer either holds or does not.

The short version

• Growth hormone is Class C because a 1996 Order added it with a group of anabolic agents ^[2].
• Its Schedule 4 Part II placement removes the possession offence; supply and production remain offences ^{[3] [4] [5]}.
• Prescription-only status and controlled-drug status are separate, and somatropin carries both ^{[1] [7]}.
• Most peptides are not scheduled because nobody has scheduled them, and that says nothing about their safety ^[6].